enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.850
-0.070 (-3.65%)
At close: Sep 9, 2026, 4:00 PM EDT
1.850
0.00 (0.00%)
After-hours: Sep 9, 2026, 4:43 PM EDT
enGene Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, enGene Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.29. The average 1-year stock price forecast is 77.84% higher than the current stock price, while the lowest is $2.00 (+8.11%) and the highest is $5.00 (+170.27%).
Price Target: $3.29 (+77.84%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for enGene Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 8 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 11 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Reiterates $2 | Hold | Reiterates | $2 | +8.11% | Sep 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +116.22% | Sep 8, 2026 |
| Morgan Stanley | Morgan Stanley | Sell Maintains n/a | Sell | Maintains | n/a | n/a | Aug 12, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $2 | Hold | Reiterates | $2 | +8.11% | Aug 12, 2026 |
| Guggenheim | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 16, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.05M
EPS This Year
-1.83
from -2.29
EPS Next Year
-1.44
from -1.83
EPS and Forward PE are based on non-GAAP adjusted numbers.